Martin David Harp

New research and EURETINA highlights from the director of the "underdog" eye clinic

Efferocytosis’ role in retinopathy is largely unknown despite knowledge of the process in other diseases.

The data were presented at the Keystone Symposium Targeting Dry Age-related Macular Degeneration: Pathophysiology and Emerging Therapies.

Yousif Subhi, MD, PhD, delivered the Ophthalmologica Lecture, "Things That Matter: An Evidence-Based Approach to AMD and CSC."

Veeral S. Sheth, MD, MBA, FASRS, FACS, discussed the outcome of the Phase 1 HELIOS trial of OTX-TKI at from this year's EURETINA congress being held in Barcelona, Spain, which takes place September 19-22, 2024.

Why having a set process for diagnostic imaging is crucial to patient outcomes

The contract research organization and technology solution is for the execution of ophthalmology clinical trials.

MK-3000, formally known as EYE103, is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wnt signaling pathway.

The one-time intravitreally delivered gene therapy is for the treatment of retinitis pigmentosa (RP).

These 4 women will feature in talks across the WIO Summer Symposium. Together they welcome all attendees to the 2024 meeting in Carlsbad, California.

PAS-nomacopan is a long-acting bispecific inhibitor of C5 and leukotriene B4 for intravitreal treatment of geographic atrophy (GA).

The trial will evaluate repeat dosing of axitinib intravitreal implant, (AXPAXLI) for the treatment of patients with wet AMD.

Richard B. Rosen, MD, from the New York Eye and Ear Infirmary of Mount Sinai discussed his presentation on sickle cell retinopathy and the measurement with dynamic OCT angiography and quad-fusion adaptive optics imaging at the annual ASRS meeting in Stockholm, Sweden.

Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.

The nOCT allows for detailed visualization of the brain's vascular anatomy.

4D-150 Is being evaluated in wet age-related macular degeneration (AMD).

Durga Borkar, MD, MMCi, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss Fas inhibition with ONL-1204 for the treatment of geographic atrophy: First-time results from a phase 1b study, which she is presenting at the ASRS meeting held in Stockholm, Sweden.

Srinivas Sai Kondapalli, MD, sat down with Sydney M. Crago, Assistant Managing Editor of Ophthalmology Times and Modern Retina, to discuss outer retinal tubulations in lesion growth for subfoveal and non-subfoveal GA.

This marks 21 years in a row the hospital has been top-ranked by the US News & World Report in the field of ophthalmology.

AAV204 is a novel adeno-associated virus (AAV) capsid from the AIM capsid library licensed by Abeona from the University of North Carolina at Chapel Hill.

The funding will go toward the continued clinical development of the company’s lead asset, AGTC-501 (laruparetigene zovaparvovec)

The deal included a total upfront consideration of $81 million, including a cash payment of approximately $65 million.

Apellis plans to seek re-examination, with a final opinion expected in fourth quarter of 2024.

The biosimilar was approved for treating patients with age-related neovascular (wet) macular degeneration (nAMD) and other serious retinal diseases.

4D-175 will be evaluated in the GAZE clinical trial, an upcoming phase 1, open-label trial.

Jennifer Lim, MD, FARVO, spoke with us about her presentation Faricimab vs aflibercept in the reduction of exudates in Y/R trials" at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

Carl Danzig, MD, spoke with us about his presentation on the 24 week results of the PRISM trials for wet AMD. He gave this presentation at Clinical Trials at the Summit meeting in Park City, Utah on June 8, 2024.

Christina Weng, MD, spoke with us about her presentation on the emerging technology of home OCT and its role in AMD. She gave this presentation at Clinical Trials at the Summit meeting being held in Park City, Utah on June 8, 2024.

The IND approval will allow the company to initiate a Phase I/IIa clinical trial for its gene therapy treatment targeting wet Age-related Macular Degeneration (AMD) including Polypoidal Choroidal Vasculopathy (PCV).